NCT05220046View on ClinicalTrials.gov

Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

July 31, 2026

Conditions
Pancreas CancerBiliary Tract CancerPsychological DistressGastrointestinal Cancer
Interventions
DRUG

Psilocybin

Psilocybin, 25mg administered orally drug during an 8-hour monitored session with supportive pre- and post- session counseling

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors
collaborator

Nebraska University Foundation

UNKNOWN

lead

University of Nebraska

OTHER